-
Company Insights
New![]()
Innovation and Patenting activity of VBI Vaccines Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of VBI Vaccines Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VBI-1901 in Recurrent Glioblastoma Multiforme (GBM)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. VBI-1901 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: VBI-1901 is under development for the...
-
Product Insights
New![]()
Net Present Value Model: Ionis Pharmaceuticals Inc’s Donidalorsen Sodium
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MRG-004A in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRG-004A in Solid Tumor Drug Details: MRG-004A is under development for the treatment of...
-
Sector Analysis
![]()
Immuno-Oncology (IO) – Thematic Intelligence
Accessing the in-depth insight from the ‘Immuno-Oncology Market' report will allow you to – Obtain immuno-oncology market assessment and forecast across multiple regions Gain insight into promising early-stage approaches. Our indication specific forecast models answer questions such as – What is the target patient pool for cell & gene therapies in each cancer indication? Which patient groups are more likely to receive these therapies? What does the cell & gene therapy clinical stage pipeline look like in each cancer indication What...
-
Product Insights
![]()
Net Present Value Model: VBI-1901
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model VBI-1901 Drug Details VBI-1901 is under...
-
Product Insights
![]()
Medulloblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Medulloblastoma Pipeline Drugs Market Report Overview Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of the brain located at the base of the skull, just above the brainstem. Symptoms associated with a Medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – VBI-2601
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VBI-2601 Drug Details VBI-2601 is under development for the treatment of hepatitis B. The...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – VBI-1901
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VBI-1901 Drug Details VBI-1901 is under development for the treatment of recurrent glioblastoma multiforme...
-
Product Insights
![]()
Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Zika Virus Infections Pipeline Drugs Market Report Overview Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications. The Zika Virus Infections pipeline drugs market research report provides comprehensive information on the Zika...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.